Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Hamouz

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Ophthalmology. Retina|August 6, 2025
Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-related Macular DegenerationScott Friedman, Nikolas London, Jan Hamouz, et al.
Ophthalmology. Retina|November 14, 2025
ReplyScott Friedman, Nikolas London, Jan Hamouz, et al.
JAMA Ophthalmology|November 19, 2020
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical TrialSe Joon Woo, Miroslav Veith, Jan Hamouz, et al.
The British Journal of Ophthalmology|October 17, 2021
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomesNeil M Bressler, Miroslav Veith, Jan Hamouz, et al.
Ophthalmology. Retina|October 10, 2024
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized TrialJan Hamouz, Agnieszka Nowosielska, Anna Święch-Zubilewicz, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Ophthalmology. Retina|August 6, 2025
Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-related Macular DegenerationScott Friedman, Nikolas London, Jan Hamouz, et al.
Ophthalmology. Retina|November 14, 2025
ReplyScott Friedman, Nikolas London, Jan Hamouz, et al.
JAMA Ophthalmology|November 19, 2020
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical TrialSe Joon Woo, Miroslav Veith, Jan Hamouz, et al.
The British Journal of Ophthalmology|October 17, 2021
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomesNeil M Bressler, Miroslav Veith, Jan Hamouz, et al.
Ophthalmology. Retina|October 10, 2024
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized TrialJan Hamouz, Agnieszka Nowosielska, Anna Święch-Zubilewicz, et al.
Pageof 1